US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

In accordance with the agreement, Philochem will get $350 million up front and could get up to $1 billion in milestone ...

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new ...

Bristol Myers' Sotyktu, a TYK2 inhibitor already approved for psoriasis, scored a win in a Phase III trial for psoriatic ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Switzerland-based Philochem and Bristol Myers Squibb (NYSE: BMY) radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...